<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-156616" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Respiratory Syncytial Virus Prefusion F (RSVPreF3) Vaccine</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Awosika</surname>
            <given-names>Ayoola O.</given-names>
          </name>
          <aff>University of Illinois College of Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Patel</surname>
            <given-names>Preeti</given-names>
          </name>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Ayoola Awosika declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Preeti Patel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>19</day>
          <month>3</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-156616.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Respiratory syncytial virus (RSV) is a prevalent respiratory pathogen that primarily affects infants, young children, older adults, and individuals with compromised immune systems. RSV is a significant cause of acute respiratory infection, lower respiratory tract disease (LRTD), clinical complications, and death in infants and older adults. The&#x000a0;U.S. Food and Drug Administration (FDA) approved the first vaccines against RSV in 2023. The recombinant subunit RSV prefusion F3 (RSVPreF3) vaccine contains the&#x000a0;RSV F glycoprotein stabilized in its prefusion (pre-F) state. By targeting the pre-F glycoprotein, the vaccine stimulates the production of neutralizing antibodies, activates both humoral and cellular immune responses, and promotes the formation of memory B and T cells. This activity provides comprehensive information on the indications, administration, dosage recommendations, mechanism of action, monitoring, adverse reactions, precautions, and contraindications associated with RSVPreF3 vaccines. This activity empowers healthcare teams to identify patients at high risk of severe RSV infection outcomes and to recommend and administer the RSVPreF3 vaccine according to nationally accepted guidelines.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify appropriate candidates for the RSVPreF3 vaccine based on age, risk factors, and clinical guidelines.</p></list-item><list-item><p>Screen patients for potential contraindications or precautions related to RSVPreF3 vaccination, considering their medical history, allergies, and current medications.</p></list-item><list-item><p>Implement&#x000a0;proper techniques for preparing, storing, handling, and administering&#x000a0;the RSVPreF3 vaccine to maintain its potency and effectiveness.</p></list-item><list-item><p>Collaborate with other healthcare professionals to effectively implement RSVPreF3 vaccination, including sharing information, monitoring vaccine coverage, addressing barriers, and integrating it into routine immunization schedules.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=156616&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=156616">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-156616.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Vaccines against the respiratory syncytial virus (RSV)&#x000a0;are indicated for adults aged 60 and older <xref ref-type="bibr" rid="article-156616.r1">[1]</xref>&#x000a0;and pregnant persons at 32 to 36 weeks gestation.<xref ref-type="bibr" rid="article-156616.r2">[2]</xref>&#x000a0;</p>
        <p>
<bold>Background Information</bold>
</p>
        <p>RSV is a common respiratory pathogen belonging to the&#x000a0;<italic toggle="yes">Paramyxoviridae&#x000a0;</italic>family. This enveloped virus possesses a single-stranded negative-sense RNA genome.<xref ref-type="bibr" rid="article-156616.r3">[3]</xref>&#x000a0;This virus has a wide-ranging impact on different age groups, including infants, young children, older adults, and individuals with compromised immune systems. RSV has a characteristic fusion protein (F protein) on its surface, facilitating its entry into host cells. RSV is primarily transmitted through respiratory droplets, which are expelled when an infected person coughs or sneezes. This virus can also survive on surfaces and objects, allowing indirect transmission through contact when individuals touch a contaminated surface and subsequently touch their face. RSV is highly contagious, and close contact with an infected individual significantly increases the risk of transmission.<xref ref-type="bibr" rid="article-156616.r4">[4]</xref></p>
        <p>Common signs and symptoms of RSV infection include a runny nose, coughing, sneezing, fever, decreased appetite, irritability, wheezing, rapid or labored breathing, and cyanosis.&#x000a0;RSV infection can result in complications, including bronchiolitis, pneumonia, and respiratory failure.<xref ref-type="bibr" rid="article-156616.r4">[4]</xref></p>
        <p>Both RSV vaccines approved for use in the US are protein-subunit vaccines&#x000a0;containing the RSV F protein stabilized in its prefusion (pre-F) state.<xref ref-type="bibr" rid="article-156616.r5">[5]</xref><xref ref-type="bibr" rid="article-156616.r6">[6]</xref> Researchers have discovered that the F protein's pre-F form is particularly adept at inducing a stronger and more effective immune response than the postfusion form.<xref ref-type="bibr" rid="article-156616.r3">[3]</xref>&#x000a0;GSK's&#x000a0;RSVPreF3 vaccine contains a&#x000a0;liposome-based adjuvant to&#x000a0;enhance the immune response to the vaccine, whereas Pfizer's RSVPreF vaccine is unadjuvanted.<xref ref-type="bibr" rid="article-156616.r5">[5]</xref><xref ref-type="bibr" rid="article-156616.r6">[6]</xref>&#x000a0;</p>
        <p>
<bold>FDA Approval</bold>
</p>
        <p>The U.S. Food and Drug Administration (FDA) approved the RSVPreF3 and RSVPreF vaccines in May 2023 for the prevention of RSV-induced lower respiratory tract disease (RSV-LRTD) in individuals aged 60 and older in the United States. The FDA approval process encompassed a comprehensive review of data obtained from preclinical studies, early-phase trials, and large-scale clinical trials. These studies thoroughly evaluated the vaccines' immunogenicity, safety, and ability to prevent RSV-related illnesses. The FDA meticulously reviewed the data to ensure&#x000a0;that both vaccines exhibited adequate efficacy and a satisfactory safety profile for their intended uses.<xref ref-type="bibr" rid="article-156616.r1">[1]</xref></p>
        <p>In August 2023, the FDA additionally approved the unadjuvanted RSVPreF vaccine for use in pregnant people between 32 and 36 weeks gestation.<xref ref-type="bibr" rid="article-156616.r2">[2]</xref>&#x000a0;The strategy of vaccinating pregnant people is based on the premise that the transplacental transfer of maternal vaccine-induced antibodies will provide passive protection to infants during the first few months of life.<xref ref-type="bibr" rid="article-156616.r7">[7]</xref>&#x000a0;Influenza and Tdap vaccines are both routinely administered to pregnant people for similar reasons.<xref ref-type="bibr" rid="article-156616.r8">[8]</xref><xref ref-type="bibr" rid="article-156616.r9">[9]</xref></p>
        <p>
<bold>Clinical Trial Results</bold>
</p>
        <p>A&#x000a0;randomized, placebo-controlled phase III trial of the adjuvanted RSVPreF3 vaccine (AReSVi-006),&#x000a0;involving 24,966 participants across 17 countries,&#x000a0;demonstrated that the immunization achieved an overall efficacy of 82.6% (96.95% CI, 57.9-94.1) against RSV-LRTD confirmed by reverse-transcriptase polymerase chain reaction (RT-PCR) over a median follow-up period of 6.7 months, successfully meeting the primary endpoint.<xref ref-type="bibr" rid="article-156616.r5">[5]</xref>&#x000a0;Moreover, the&#x000a0;adjuvanted vaccine effectively prevented severe RSV-LRTD (94.1%, 95% CI, 62.4-99.9) and RSV-related acute respiratory infection (71.7%, 95% CI, 56.2-82.3).<xref ref-type="bibr" rid="article-156616.r5">[5]</xref>&#x000a0;The vaccine's efficacy remained consistent across both RSV A and B subtypes, diverse age groups, and coexisting conditions. The vaccine demonstrated a higher reactogenicity than the placebo, although most adverse events reported were transient and of mild-to-moderate severity.<xref ref-type="bibr" rid="article-156616.r5">[5]</xref>&#x000a0;Notably, the incidences of serious adverse events and potential immune-mediated diseases were comparable between the vaccine and placebo groups.<xref ref-type="bibr" rid="article-156616.r5">[5]</xref></p>
        <p>A multicenter phase III clinical trial of 34,284 participants (RENOIR) found similar results for the efficacy and safety of the unadjuvanted RSVPreF vaccine in adults aged 60 and older.<xref ref-type="bibr" rid="article-156616.r1">[1]</xref>&#x000a0;The incidence of local reactions was higher among RSVPreF vaccine recipients than among placebo groups, but the rates of systemic and severe adverse events were similar between vaccine and placebo groups.<xref ref-type="bibr" rid="article-156616.r6">[6]</xref></p>
        <p>Extensive vaccine testing, including preclinical studies and phase I&#x000a0;and II trials conducted on non-pregnant and pregnant women, demonstrated a favorable safety profile and robust immunogenicity.<xref ref-type="bibr" rid="article-156616.r10">[10]</xref>&#x000a0;A&#x000a0;randomized, placebo-controlled phase III clinical trial involving&#x000a0;7,358 pregnant individuals between the 24th and 36th weeks of gestation (MATISSE) assessed&#x000a0;RSVPreF vaccine efficacy in preventing medically attended RSV-LRTD among participants' infants during the first 90, 120, 150, and 180 days following birth.<xref ref-type="bibr" rid="article-156616.r7">[7]</xref>&#x000a0;The study found an 81.8% vaccine efficacy against severe RSV-LRTD within 90 days after birth (95% CI, 40.6-96.3) and 57.1% efficacy against RSV-LRTD of any severity within the same period (95% CI, 14.7-79.8).&#x000a0;These efficacies dropped to 69.4% (95% CI, 44.3-84.1) and 51.3% (95% CI, 29.4-66.8), respectively, by 180 days after birth.<xref ref-type="bibr" rid="article-156616.r7">[7]</xref>&#x000a0;As with the 60 and older age cohort, the incidence of local reactions was higher among vaccine recipients than in the placebo group; however, rates of systemic and severe adverse events were similar in both groups. The incidence of adverse events occurring among infants within 1 month of birth was similar between the vaccine and placebo groups.<xref ref-type="bibr" rid="article-156616.r7">[7]</xref></p>
      </sec>
      <sec id="article-156616.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>RSVPreF3 and RSVPreF vaccines stimulate the humoral and cellular immune responses and provide immunity against RSV by targeting the pre-F forms of the F proteins present on the surface of RSV subgroups A and B.&#x000a0;The F protein is pivotal in viral fusion and facilitates the entry of the virus into the host cells.<xref ref-type="bibr" rid="article-156616.r11">[11]</xref>&#x000a0;</p>
        <p>The vaccines&#x000a0;stimulate the production of neutralizing antibodies that recognize and bind to the pre-F protein, blocking viral attachment and fusion with host cells.<xref ref-type="bibr" rid="article-156616.r12">[12]</xref>&#x000a0;As a result, virus neutralization occurs, significantly lowering the risk of infection and subsequent viral replication.<xref ref-type="bibr" rid="article-156616.r13">[13]</xref>&#x000a0;In addition, the vaccine facilitates the transplacental transfer of maternal antibodies to infants, providing passive protection against RSV infection in the first 3-6 months of life.<xref ref-type="bibr" rid="article-156616.r7">[7]</xref></p>
        <p>The RSVPreF3 and RSVPreF vaccines also activate the cellular immune response by stimulating polyfunctional CD4 T cells and&#x000a0;memory B cells. These memory cells retain a "memory" of the RSV antigens encountered during vaccination, enabling a rapid and robust immune response upon subsequent exposure to RSV.<xref ref-type="bibr" rid="article-156616.r14">[14]</xref></p>
        <p>The AS01 adjuvant contained in the RSVPreF3 vaccine is a liposomal formulation that combines 2 immunostimulants that are QS-21, extracted from the bark of the Quillaja saponaria tree, and MPL, a synthetic derivative of bacterial lipopolysaccharide (<italic toggle="yes">Salmonella</italic> Minnesota strain).<xref ref-type="bibr" rid="article-156616.r15">[15]</xref> The AS01 adjuvant enhances the immune response to the RSVPreF3 antigen by activating innate immune cells, inducing cytokine production, promoting antigen presentation, and stimulating humoral and cellular immunity.<xref ref-type="bibr" rid="article-156616.r15">[15]</xref>&#x000a0;Moreover, the AS01 adjuvant also helps overcome the natural decline in immunity that accompanies aging by amplifying the magnitude and quality of the antibody response.<xref ref-type="bibr" rid="article-156616.r15">[15]</xref></p>
      </sec>
      <sec id="article-156616.s4" sec-type="Administration">
        <title>Administration</title>
        <p><bold>Storage</bold>: Before reconstitution,&#x000a0;both&#x000a0;vaccines and their diluents should be stored in refrigerators and maintained between 2 and 8 &#x000b0;C (36-46 &#x000b0;F) in their original packaging to shield them from light. Once reconstituted, the vaccine should be administered immediately. If not administered immediately, the vaccine must be protected from light and either stored in the refrigerator or at room temperature. Discard any vaccine that is not used within 4 hours of reconstitution.</p>
        <p><bold>Preparation</bold>: Both&#x000a0;vaccines are prepared by reconstitution.&#x000a0;RSVPreF3 is reconstituted with the adjuvant solution, whereas RSVPreF is reconstituted with sterile water.<xref ref-type="bibr" rid="article-156616.r5">[5]</xref><xref ref-type="bibr" rid="article-156616.r16">[16]</xref>&#x000a0;Use only the diluent supplied by the manufacturer.</p>
        <p><bold>Route</bold>:&#x000a0;Intramuscular injection</p>
        <p><bold>Strength</bold>: Each dose contains 120 &#x003bc;g of vaccine. In addition, the adjuvanted RSVPreF3 vaccine contains 25&#x000a0;&#x003bc;g of QS-21 and 25 &#x003bc;g of MPL.<xref ref-type="bibr" rid="article-156616.r5">[5]</xref></p>
        <p><bold>Dose</bold>: A single dose of 0.5 mL is recommended for adults after reconstitution.<xref ref-type="bibr" rid="article-156616.r1">[1]</xref><xref ref-type="bibr" rid="article-156616.r2">[2]</xref></p>
        <p><bold>Coadministration with other vaccines</bold>: Either RSVPreF3 or RSVPreF may be administered at the same visit with any other adult vaccine.<xref ref-type="bibr" rid="article-156616.r1">[1]</xref><xref ref-type="bibr" rid="article-156616.r2">[2]</xref></p>
        <p><bold>Considerations for older adults</bold>:&#x000a0;Either the adjuvanted RSVPreF3 or the unadjuvanted RSVPreF may be administered to adults aged 60 or older.<xref ref-type="bibr" rid="article-156616.r1">[1]</xref> The U.S. Centers for Disease Control and Prevention (CDC) recommends that adults aged 60 years and older may receive RSV vaccination based on shared clinical decision-making between the clinician and patient. The decision whether to vaccinate should consider&#x000a0;the patient's risks for severe RSV-LRTD,&#x000a0;their preferences and values, and the clinician's discretion.&#x000a0;Risk factors for severe RSV-LRTD include:<xref ref-type="bibr" rid="article-156616.r1">[1]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Chronic&#x000a0;obstructive pulmonary disease</p>
          </list-item>
          <list-item>
            <p>Moderate or severe immunocompromise</p>
          </list-item>
          <list-item>
            <p>Congestive heart failure</p>
          </list-item>
          <list-item>
            <p>Stroke</p>
          </list-item>
          <list-item>
            <p>Hematologic disorders</p>
          </list-item>
          <list-item>
            <p>Chronic kidney disease</p>
          </list-item>
          <list-item>
            <p>Medical frailty</p>
          </list-item>
          <list-item>
            <p>Residence in a long-term care facility</p>
          </list-item>
        </list>
        <p><bold>Considerations for pregnant people</bold>: Only the unadjuvanted RSVPreF vaccine is currently indicated for vaccination of pregnant people.<xref ref-type="bibr" rid="article-156616.r2">[2]</xref>&#x000a0;The CDC recommends that pregnant people receive a one-time dose at 32-36 weeks gestation in September through January in the continental U.S. RSV season varies&#x000a0;by climate, so clinicians practicing outside the continental U.S. should follow their local, state, or territorial guidance on optimal timing of vaccination. Currently, CDC guidance does not address whether patients should receive additional doses of the RSVPreF vaccine during subsequent pregnancies; the CDC may update its guidance in the future to address this scenario should additional data become available.<xref ref-type="bibr" rid="article-156616.r2">[2]</xref></p>
        <p><bold>Use of&#x000a0;nirsevimab in infants following maternal RSVPreF vaccination</bold>: Nirsevimab is a long-acting monoclonal antibody against RSV for infants aged less than 8 months who are born during or entering their first RSV season and for infants and toddlers aged 8-19 months at high risk of severe RSV disease who are entering their second RSV season.<xref ref-type="bibr" rid="article-156616.r17">[17]</xref>&#x000a0;The CDC recommends <italic toggle="yes">either</italic>&#x000a0;RSVPreF vaccination during pregnancy <italic toggle="yes">or</italic> nirsevimab administration to infants younger than 8 months, but not both.<xref ref-type="bibr" rid="article-156616.r2">[2]</xref>&#x000a0;Clinicians providing prenatal care to pregnant people during RSV season should discuss the advantages and disadvantages of RSVPreF&#x000a0;vaccine and nirsevimab with their patients. However, infants and toddlers aged 8&#x000a0;to 19 months at high risk of severe RSV disease may still receive nirsevimab in their second RSV season regardless of whether their parent received RSVPreF during pregnancy.<xref ref-type="bibr" rid="article-156616.r2">[2]</xref></p>
      </sec>
      <sec id="article-156616.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>The adverse effects of the RSVPreF3 and RSVPreF vaccines have undergone evaluation through numerous clinical trials involving diverse populations, including non-pregnant women, pregnant women, and older adults.<xref ref-type="bibr" rid="article-156616.r5">[5]</xref><xref ref-type="bibr" rid="article-156616.r6">[6]</xref><xref ref-type="bibr" rid="article-156616.r7">[7]</xref><xref ref-type="bibr" rid="article-156616.r18">[18]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Local reactions at the injection site</bold>: The adjuvanted RSVPreF3 vaccine is more reactogenic than the unadjuvanted RSVPreF vaccine, although local reactions at the injection site are commonly reported adverse effects of both vaccines.<xref ref-type="bibr" rid="article-156616.r1">[1]</xref> Typically, these reactions are mild to moderate and may manifest as pain, tenderness, swelling, redness, or itching at the injection site. Pain is the most common local reaction to either vaccine, occurring among approximately 60% to 80% of RSVPreF3 vaccine recipients and 10% to 40% of RSVPreF vaccine recipients.<xref ref-type="bibr" rid="article-156616.r6">[6]</xref><xref ref-type="bibr" rid="article-156616.r7">[7]</xref><xref ref-type="bibr" rid="article-156616.r10">[10]</xref>&#x000a0;These local reactions&#x000a0;typically resolve spontaneously within&#x000a0;1-2&#x000a0;days without specific treatment; however, 3.8% of RSVPreF3 vaccine recipients and 1.0% of RSVPreF vaccine recipients reported severe reactogenicity events during clinical trials.<xref ref-type="bibr" rid="article-156616.r1">[1]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Systemic reactions</bold>: Systemic reactions following RSVPreF3 or RSVPreF vaccination are generally mild and transient. Common systemic reactions may include fever, headache, fatigue, muscle pain, joint pain, chills, or general malaise. The most common systemic reactions are fatigue and headache experienced by approximately 25% to 35% of RSVPreF3 vaccine recipients and approximately 10% to 20% of RSVPreF vaccine recipients.<xref ref-type="bibr" rid="article-156616.r5">[5]</xref><xref ref-type="bibr" rid="article-156616.r6">[6]</xref>&#x000a0;These symptoms are typically self-limiting and resolve within a short period.</p>
          </list-item>
          <list-item>
            <p><bold>Serious adverse events</bold>: Overall, the rates of serious adverse events&#x000a0;in the RSVPreF3 and RSVPre3 vaccine clinical trials were similar between the vaccine and placebo groups.<xref ref-type="bibr" rid="article-156616.r5">[5]</xref><xref ref-type="bibr" rid="article-156616.r6">[6]</xref><xref ref-type="bibr" rid="article-156616.r7">[7]</xref>&#x000a0;However, the FDA and CDC noted a small but statistically significant increase in atrial fibrillation among RSVPreF3 and RSVPreF vaccine recipients aged 60 years or older compared with placebo recipients in the same age group. Postmarketing studies and surveillance are ongoing to better evaluate the risk of atrial fibrillation after vaccination against RSV.<xref ref-type="bibr" rid="article-156616.r1">[1]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Allergic reactions</bold>: Although rare, allergic reactions following RSVPreF3 or RSVPreF vaccination may manifest as hives, itching, swelling of the face or throat, difficulty breathing, or wheezing. Although severe allergic reactions, known as anaphylaxis, are infrequent, they can potentially happen. Anaphylaxis is a severe, life-threatening allergic reaction characterized by difficulty breathing, rapid heartbeat, dizziness, and loss of consciousness. Immediate medical attention is required if anaphylaxis is suspected.</p>
          </list-item>
          <list-item>
            <p><bold>Pregnancy complications</bold>: Infants&#x000a0;whose parents received the RSVPreF vaccine during pregnancy had similar rates of prematurity, low birth rate, developmental delay,&#x000a0;and other serious adverse events within 24 months of birth compared to&#x000a0;those whose parents received a placebo. However, people with high-risk pregnancies were excluded from the clinical trials, so data is lacking on the risks of RSV vaccination in this group.<xref ref-type="bibr" rid="article-156616.r7">[7]</xref>&#x000a0;A small and statistically insignificant increase in preeclampsia was observed in the RSVPreF vaccine group (1.8%), compared with the placebo group (1.4%).<xref ref-type="bibr" rid="article-156616.r7">[7]</xref>&#x000a0;Postmarketing studies and surveillance are ongoing to better evaluate the risk of preeclampsia following RSVPreF vaccination during pregnancy.<xref ref-type="bibr" rid="article-156616.r1">[1]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-156616.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>RSVPreF3 and RSVPreF vaccines should not be administered to individuals with a history of severe allergic reactions, including anaphylaxis, to any vaccine component.<xref ref-type="bibr" rid="article-156616.r1">[1]</xref><xref ref-type="bibr" rid="article-156616.r2">[2]</xref></p>
        <p>
<bold>Precautions&#x000a0;</bold>
</p>
        <p>Acute illness:&#x000a0;Vaccination should be temporarily delayed in persons experiencing moderate-to-severe acute illness until their illness has resolved or stabilized.<xref ref-type="bibr" rid="article-156616.r1">[1]</xref> Vaccination does not need to be delayed in persons with mild or chronic illnesses.</p>
        <p>Risk of preterm birth:&#x000a0;The current data do not provide enough information to definitively confirm or rule out a cause-and-effect relationship between preterm birth and the use of RSVPreF. To mitigate any potential risk of preterm birth before 32 weeks of gestation, it is recommended to administer RSVPreF to pregnant individuals within the gestational age range of 32 to 36 weeks. Notably, pregnant individuals at an elevated risk of preterm birth were typically not included in clinical trials.<xref ref-type="bibr" rid="article-156616.r1">[1]</xref></p>
      </sec>
      <sec id="article-156616.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>The CDC conducts comprehensive vaccine safety monitoring to assess and evaluate the occurrence of any adverse effects, including cases of Guillain-Barr&#x000e9; syndrome,&#x000a0;preterm birth, hypertensive disorders of pregnancy, transverse myelitis, acute disseminated encephalomyelitis,&#x000a0;and other inflammatory neurologic events after RSV vaccination.<xref ref-type="bibr" rid="article-156616.r1">[1]</xref><xref ref-type="bibr" rid="article-156616.r2">[2]</xref>&#x000a0;This ongoing monitoring is essential in detecting and identifying rare or long-term adverse effects that may not have been observed during clinical trials. In accordance with FDA requirements, GSK will conduct a postmarketing study evaluating the risk of atrial fibrillation after receipt of the RSVPreF3 vaccine, and Pfizer will conduct postmarketing studies assessing the risks of atrial fibrillation, preterm birth, and hypertensive disorders of pregnancy following RSVPreF vaccination.<xref ref-type="bibr" rid="article-156616.r1">[1]</xref><xref ref-type="bibr" rid="article-156616.r2">[2]</xref></p>
        <p>US healthcare providers should report any clinically significant adverse events after vaccination to the Vaccine Adverse Events Reporting System (VAERS) at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://vaers.hhs.gov/index.html">https://vaers.hhs.gov/index.html</ext-link>.<xref ref-type="bibr" rid="article-156616.r1">[1]</xref></p>
      </sec>
      <sec id="article-156616.s8" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>RSVPreF3 and RSVPreF vaccines are important new tools to reduce morbidity and mortality caused by RSV among older adults and infants. Interdisciplinary collaboration and effective communication among healthcare professionals is critical to ensure the safe and efficient administration of these&#x000a0;vaccines.&#x000a0;</p>
        <p>Vaccine education and training: Healthcare professionals across various disciplines,&#x000a0;including physicians, nurses, pharmacists, and allied health personnel, should receive comprehensive education and training on RSVPreF3 and RSVPreF vaccines. This education should comprehensively help clinicians understand the vaccines' indications, contraindications, dosage, administration technique, and potential adverse events. Regular updates on the most recent guidelines and recommendations should be provided to ensure all team members are well-informed and up-to-date with the latest information. Non-clinical staff should also be educated to ensure they provide consistent vaccine messaging to patients.<xref ref-type="bibr" rid="article-156616.r19">[19]</xref></p>
        <p>Shared decision-making approach:&#x000a0;Interdisciplinary collaboration includes engaging in shared decision-making with patients and their caregivers. Healthcare professionals should communicate the benefits, risks, and potential outcomes of RSVPreF3 and RSVPreF vaccination to patients and their family members. This collaborative approach fosters open dialogue, addresses concerns or questions, and ensures that patients and caregivers are actively involved in decision-making.<xref ref-type="bibr" rid="article-156616.r1">[1]</xref></p>
        <p>Vaccine administration protocols: Interdisciplinary collaboration is essential in developing standardized protocols for administering the RSVPreF3 and RSVPreF vaccines. These protocols should include guidelines on the vaccine's proper storage, preparation, handling, and administration techniques. Clear communication channels should be established to ensure that all healthcare professionals involved in the administration process are well-informed and consistently adhere to these protocols.</p>
        <p>Adverse event reporting: Interdisciplinary collaboration is crucial in monitoring and reporting vaccine adverse events. All healthcare professionals should be familiar with the established reporting mechanisms and promptly report any suspected adverse events to the appropriate regulatory authorities. By sharing this vital information, healthcare professionals enhance post-marketing surveillance and facilitate the ongoing evaluation of vaccine safety.</p>
      </sec>
      <sec id="article-156616.s9">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=156616&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=156616">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/156616/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=156616">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-156616.s10">
        <title>References</title>
        <ref id="article-156616.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Melgar</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Britton</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Roper</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Talbot</surname>
                <given-names>HK</given-names>
              </name>
              <name>
                <surname>Long</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Kotton</surname>
                <given-names>CN</given-names>
              </name>
              <name>
                <surname>Havers</surname>
                <given-names>FP</given-names>
              </name>
            </person-group>
            <article-title>Use of Respiratory Syncytial Virus Vaccines in Older Adults: Recommendations of the Advisory Committee on Immunization Practices - United States, 2023.</article-title>
            <source>MMWR Morb Mortal Wkly Rep</source>
            <year>2023</year>
            <month>Jul</month>
            <day>21</day>
            <volume>72</volume>
            <issue>29</issue>
            <fpage>793</fpage>
            <page-range>793-801</page-range>
            <pub-id pub-id-type="pmid">37471262</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156616.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fleming-Dutra</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Roper</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Prill</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Ortega-Sanchez</surname>
                <given-names>IR</given-names>
              </name>
              <name>
                <surname>Moulia</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Wallace</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Godfrey</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Broder</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Tepper</surname>
                <given-names>NK</given-names>
              </name>
              <name>
                <surname>Brooks</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>S&#x000e1;nchez</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Kotton</surname>
                <given-names>CN</given-names>
              </name>
              <name>
                <surname>Mahon</surname>
                <given-names>BE</given-names>
              </name>
              <name>
                <surname>Long</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>McMorrow</surname>
                <given-names>ML</given-names>
              </name>
            </person-group>
            <article-title>Use of the Pfizer Respiratory Syncytial Virus Vaccine During Pregnancy for the Prevention of Respiratory Syncytial Virus-Associated Lower Respiratory Tract Disease in Infants: Recommendations of the Advisory Committee on Immunization Practices - United States, 2023.</article-title>
            <source>MMWR Morb Mortal Wkly Rep</source>
            <year>2023</year>
            <month>Oct</month>
            <day>13</day>
            <volume>72</volume>
            <issue>41</issue>
            <fpage>1115</fpage>
            <page-range>1115-1122</page-range>
            <pub-id pub-id-type="pmid">37824423</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156616.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Qiu</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Luo</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Yan</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ji</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Development of mRNA vaccines against respiratory syncytial virus (RSV).</article-title>
            <source>Cytokine Growth Factor Rev</source>
            <year>2022</year>
            <month>Dec</month>
            <volume>68</volume>
            <fpage>37</fpage>
            <page-range>37-53</page-range>
            <pub-id pub-id-type="pmid">36280532</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156616.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shang</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Tan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ma</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Respiratory syncytial virus: from pathogenesis to potential therapeutic strategies.</article-title>
            <source>Int J Biol Sci</source>
            <year>2021</year>
            <volume>17</volume>
            <issue>14</issue>
            <fpage>4073</fpage>
            <page-range>4073-4091</page-range>
            <pub-id pub-id-type="pmid">34671221</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156616.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Papi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ison</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Langley</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Leroux-Roels</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Martinon-Torres</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Schwarz</surname>
                <given-names>TF</given-names>
              </name>
              <name>
                <surname>van Zyl-Smit</surname>
                <given-names>RN</given-names>
              </name>
              <name>
                <surname>Campora</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Dezutter</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>de Schrevel</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Fissette</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>David</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Van der Wielen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kostanyan</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Hulstr&#x000f8;m</surname>
                <given-names>V</given-names>
              </name>
              <collab>AReSVi-006 Study Group</collab>
            </person-group>
            <article-title>Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults.</article-title>
            <source>N Engl J Med</source>
            <year>2023</year>
            <month>Feb</month>
            <day>16</day>
            <volume>388</volume>
            <issue>7</issue>
            <fpage>595</fpage>
            <page-range>595-608</page-range>
            <pub-id pub-id-type="pmid">36791160</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156616.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Walsh</surname>
                <given-names>EE</given-names>
              </name>
              <name>
                <surname>P&#x000e9;rez Marc</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Zareba</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Falsey</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Jiang</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Patton</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Polack</surname>
                <given-names>FP</given-names>
              </name>
              <name>
                <surname>Llapur</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Doreski</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Ilangovan</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>R&#x000e4;met</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fukushima</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Hussen</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Bont</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Cardona</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>DeHaan</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Castillo Villa</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ingilizova</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Eiras</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Mikati</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>RN</given-names>
              </name>
              <name>
                <surname>Schneider</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Cooper</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Koury</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Lino</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Jansen</surname>
                <given-names>KU</given-names>
              </name>
              <name>
                <surname>Swanson</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Gurtman</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gruber</surname>
                <given-names>WC</given-names>
              </name>
              <name>
                <surname>Schmoele-Thoma</surname>
                <given-names>B</given-names>
              </name>
              <collab>RENOIR Clinical Trial Group</collab>
            </person-group>
            <article-title>Efficacy and Safety of a Bivalent RSV Prefusion F Vaccine in Older Adults.</article-title>
            <source>N Engl J Med</source>
            <year>2023</year>
            <month>Apr</month>
            <day>20</day>
            <volume>388</volume>
            <issue>16</issue>
            <fpage>1465</fpage>
            <page-range>1465-1477</page-range>
            <pub-id pub-id-type="pmid">37018468</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156616.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kampmann</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Madhi</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Munjal</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Sim&#x000f5;es</surname>
                <given-names>EAF</given-names>
              </name>
              <name>
                <surname>Pahud</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Llapur</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Baker</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>P&#x000e9;rez Marc</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Radley</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Shittu</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Glanternik</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Snaggs</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Baber</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zachariah</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Barnabas</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Fausett</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Adam</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Perreras</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Van Houten</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Kantele</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Bont</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Otsuki</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Vargas</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Gullam</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Tapiero</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Stein</surname>
                <given-names>RT</given-names>
              </name>
              <name>
                <surname>Polack</surname>
                <given-names>FP</given-names>
              </name>
              <name>
                <surname>Zar</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Staerke</surname>
                <given-names>NB</given-names>
              </name>
              <name>
                <surname>Duron Padilla</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Richmond</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Koury</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Schneider</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kalinina</surname>
                <given-names>EV</given-names>
              </name>
              <name>
                <surname>Cooper</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Jansen</surname>
                <given-names>KU</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Swanson</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Gruber</surname>
                <given-names>WC</given-names>
              </name>
              <name>
                <surname>Gurtman</surname>
                <given-names>A</given-names>
              </name>
              <collab>MATISSE Study Group</collab>
            </person-group>
            <article-title>Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants.</article-title>
            <source>N Engl J Med</source>
            <year>2023</year>
            <month>Apr</month>
            <day>20</day>
            <volume>388</volume>
            <issue>16</issue>
            <fpage>1451</fpage>
            <page-range>1451-1464</page-range>
            <pub-id pub-id-type="pmid">37018474</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156616.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Grohskopf</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Blanton</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Ferdinands</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Chung</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Broder</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Talbot</surname>
                <given-names>HK</given-names>
              </name>
              <name>
                <surname>Morgan</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Fry</surname>
                <given-names>AM</given-names>
              </name>
            </person-group>
            <article-title>Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2022-23 Influenza Season.</article-title>
            <source>MMWR Recomm Rep</source>
            <year>2022</year>
            <month>Aug</month>
            <day>26</day>
            <volume>71</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-28</page-range>
            <pub-id pub-id-type="pmid">36006864</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156616.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <collab>Centers for Disease Control and Prevention (CDC)</collab>
            <article-title>Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) in pregnant women--Advisory Committee on Immunization Practices (ACIP), 2012.</article-title>
            <source>MMWR Morb Mortal Wkly Rep</source>
            <year>2013</year>
            <month>Feb</month>
            <day>22</day>
            <volume>62</volume>
            <issue>7</issue>
            <fpage>131</fpage>
            <page-range>131-5</page-range>
            <pub-id pub-id-type="pmid">23425962</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156616.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sim&#x000f5;es</surname>
                <given-names>EAF</given-names>
              </name>
              <name>
                <surname>Center</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Tita</surname>
                <given-names>ATN</given-names>
              </name>
              <name>
                <surname>Swanson</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Radley</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Houghton</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>McGrory</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Gomme</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Roberts</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Scott</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Jansen</surname>
                <given-names>KU</given-names>
              </name>
              <name>
                <surname>Gruber</surname>
                <given-names>WC</given-names>
              </name>
              <name>
                <surname>Dormitzer</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>Gurtman</surname>
                <given-names>AC</given-names>
              </name>
            </person-group>
            <article-title>Prefusion F Protein-Based Respiratory Syncytial Virus Immunization in Pregnancy.</article-title>
            <source>N Engl J Med</source>
            <year>2022</year>
            <month>Apr</month>
            <day>28</day>
            <volume>386</volume>
            <issue>17</issue>
            <fpage>1615</fpage>
            <page-range>1615-1626</page-range>
            <pub-id pub-id-type="pmid">35476650</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156616.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Walsh</surname>
                <given-names>EE</given-names>
              </name>
              <name>
                <surname>Falsey</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Scott</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Gurtman</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Zareba</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Jansen</surname>
                <given-names>KU</given-names>
              </name>
              <name>
                <surname>Gruber</surname>
                <given-names>WC</given-names>
              </name>
              <name>
                <surname>Dormitzer</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>Swanson</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Radley</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Gomme</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Cooper</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Schmoele-Thoma</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>A Randomized Phase 1/2 Study of a Respiratory Syncytial Virus Prefusion F Vaccine.</article-title>
            <source>J Infect Dis</source>
            <year>2022</year>
            <month>Apr</month>
            <day>19</day>
            <volume>225</volume>
            <issue>8</issue>
            <fpage>1357</fpage>
            <page-range>1357-1366</page-range>
            <pub-id pub-id-type="pmid">34932102</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156616.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schwarz</surname>
                <given-names>TF</given-names>
              </name>
              <name>
                <surname>McPhee</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Launay</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Leroux-Roels</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Talli</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Picciolato</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gao</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Cai</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Nguyen</surname>
                <given-names>TL</given-names>
              </name>
              <name>
                <surname>Dieussaert</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Schmidt</surname>
                <given-names>AC</given-names>
              </name>
            </person-group>
            <article-title>Immunogenicity and Safety of 3 Formulations of a Respiratory Syncytial Virus Candidate Vaccine in Nonpregnant Women: A Phase 2, Randomized Trial.</article-title>
            <source>J Infect Dis</source>
            <year>2019</year>
            <month>Oct</month>
            <day>22</day>
            <volume>220</volume>
            <issue>11</issue>
            <fpage>1816</fpage>
            <page-range>1816-1825</page-range>
            <pub-id pub-id-type="pmid">31418022</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156616.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schmoele-Thoma</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Zareba</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Jiang</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Maddur</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Danaf</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Mann</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Eze</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Fok-Seang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kabir</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Catchpole</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Scott</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Gurtman</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Jansen</surname>
                <given-names>KU</given-names>
              </name>
              <name>
                <surname>Gruber</surname>
                <given-names>WC</given-names>
              </name>
              <name>
                <surname>Dormitzer</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>Swanson</surname>
                <given-names>KA</given-names>
              </name>
            </person-group>
            <article-title>Vaccine Efficacy in Adults in a Respiratory Syncytial Virus Challenge Study.</article-title>
            <source>N Engl J Med</source>
            <year>2022</year>
            <month>Jun</month>
            <day>23</day>
            <volume>386</volume>
            <issue>25</issue>
            <fpage>2377</fpage>
            <page-range>2377-2386</page-range>
            <pub-id pub-id-type="pmid">35731653</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156616.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Crank</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Ruckwardt</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Morabito</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Phung</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Costner</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Holman</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Hickman</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Berkowitz</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>Gordon</surname>
                <given-names>IJ</given-names>
              </name>
              <name>
                <surname>Yamshchikov</surname>
                <given-names>GV</given-names>
              </name>
              <name>
                <surname>Gaudinski</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Kumar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Moin</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Hill</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>DiPiazza</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Schwartz</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Kueltzo</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Cooper</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Stein</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Carlton</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Gall</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Nason</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Kwong</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Mascola</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>McLellan</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Ledgerwood</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Graham</surname>
                <given-names>BS</given-names>
              </name>
              <collab>VRC 317 Study Team</collab>
            </person-group>
            <article-title>A proof of concept for structure-based vaccine design targeting RSV in humans.</article-title>
            <source>Science</source>
            <year>2019</year>
            <month>Aug</month>
            <day>02</day>
            <volume>365</volume>
            <issue>6452</issue>
            <fpage>505</fpage>
            <page-range>505-509</page-range>
            <pub-id pub-id-type="pmid">31371616</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156616.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Awar</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mylonakis</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>In older adults, an AS01<sub>E</sub>-adjuvanted RSVPreF3 OA vaccine reduced RSV-related lower respiratory tract disease.</article-title>
            <source>Ann Intern Med</source>
            <year>2023</year>
            <month>Jun</month>
            <volume>176</volume>
            <issue>6</issue>
            <fpage>JC62</fpage>
            <pub-id pub-id-type="pmid">37276600</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156616.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Baber</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Arya</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Moodley</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Jaques</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jiang</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Swanson</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Cooper</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Maddur</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Loschko</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gurtman</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jansen</surname>
                <given-names>KU</given-names>
              </name>
              <name>
                <surname>Gruber</surname>
                <given-names>WC</given-names>
              </name>
              <name>
                <surname>Dormitzer</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>Schmoele-Thoma</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>A Phase 1/2 Study of a Respiratory Syncytial Virus Prefusion F Vaccine With and Without Adjuvant in Healthy Older Adults.</article-title>
            <source>J Infect Dis</source>
            <year>2022</year>
            <month>Dec</month>
            <day>13</day>
            <volume>226</volume>
            <issue>12</issue>
            <fpage>2054</fpage>
            <page-range>2054-2063</page-range>
            <pub-id pub-id-type="pmid">35543281</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156616.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jones</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Fleming-Dutra</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Prill</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Roper</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Brooks</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>S&#x000e1;nchez</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Kotton</surname>
                <given-names>CN</given-names>
              </name>
              <name>
                <surname>Mahon</surname>
                <given-names>BE</given-names>
              </name>
              <name>
                <surname>Meyer</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Long</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>McMorrow</surname>
                <given-names>ML</given-names>
              </name>
            </person-group>
            <article-title>Use of Nirsevimab for the Prevention of Respiratory Syncytial Virus Disease Among Infants and Young Children: Recommendations of the Advisory Committee on Immunization Practices - United States, 2023.</article-title>
            <source>MMWR Morb Mortal Wkly Rep</source>
            <year>2023</year>
            <month>Aug</month>
            <day>25</day>
            <volume>72</volume>
            <issue>34</issue>
            <fpage>920</fpage>
            <page-range>920-925</page-range>
            <pub-id pub-id-type="pmid">37616235</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156616.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Leroux-Roels</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Steenackers</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Essink</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Vandermeulen</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Fogarty</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Andrews</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Kerwin</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>David</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Fissette</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Vanden Abeele</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Collete</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>de Heusch</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Salaun</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>De Schrevel</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Koch</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Verheust</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Dezutter</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Struyf</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Mesaros</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Tica</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hulstr&#x000f8;m</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Safety and Immunogenicity of a Respiratory Syncytial Virus Prefusion F (RSVPreF3) Candidate Vaccine in Older Adults: Phase 1/2 Randomized Clinical Trial.</article-title>
            <source>J Infect Dis</source>
            <year>2023</year>
            <month>Mar</month>
            <day>28</day>
            <volume>227</volume>
            <issue>6</issue>
            <fpage>761</fpage>
            <page-range>761-772</page-range>
            <pub-id pub-id-type="pmid">35904987</pub-id>
          </element-citation>
        </ref>
        <ref id="article-156616.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stinchfield</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kurland</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gigi Chawla</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Optimizing Your Pediatric Office for Vaccine Confidence.</article-title>
            <source>Pediatr Clin North Am</source>
            <year>2023</year>
            <month>Apr</month>
            <volume>70</volume>
            <issue>2</issue>
            <fpage>343</fpage>
            <page-range>343-357</page-range>
            <pub-id pub-id-type="pmid">36841601</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
